Monday, August 31, 2015
The Michael J. Fox Foundation for Parkinson’s research (MJFF) has launched the Parkinson’s Disease Research Tools Consortium. MJFF and seven industry partners have organized to grow the Foundation’s ongoing efforts to better understand existing tools—such as preclinical models, antibodies and cell lines—and their use in laboratory experiments, as well as to develop new tools to address unmet challenges.
Amicus Therapeutics, a biopharmaceutical company developing therapies for rare and orphan diseases, is collaborating with Biogen Idec to discover, develop and commercialize novel small molecules for the treatment of Parkinson’s disease. The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson’s.